List of Studies ( Metabolite:beta-Vinyl acrylic acid)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004291 | AN007135 | Metabolomics analysis of Plasmodium falciparum asexual-stage parasites treated with plasmepsin V peptidomimetics - 16 hour treatment | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003144 | AN005159 | On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST003053 | AN005007 | Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics | Bacterial cells | Staphylococcus aureus | Bacterial infection | Monash University | LC-MS |
| ST002926 | AN004798 | Multi-“omics” analysis reveals the orphan P. falciparum protein kinase PfPK8 regulates multi-gene family expression | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002792 | AN004542 | Chemoproteomics validates selective targeting of Plasmodium M1 alanyl aminopeptidase as a cross-species strategy to treat malaria | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002108 | AN003448 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 3) | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST002107 | AN003446 | Genetic and chemical validation of Plasmodium falciparum aminopeptidase PfA-M17 as a drug target in the hemoglobin digestion pathway (Part 2) | Blood | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001788 | AN002900 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | LC-MS | |
| ST001304 | AN002172 | Multi-omics analysis delineates the distinct functions of sub-cellular acetyl-CoA pools in Toxoplasma gondii | Fibroblast cells | Toxoplasma gondii | Parasitic infection | Monash University | LC-MS |
| ST001205 | AN002006 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001205 | AN002006 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001204 | AN002004 | Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001204 | AN002004 | Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001202 | AN002000 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | LC-MS |
| ST001202 | AN002000 | Peroxide antimalarial treatment timecourse on ring-stage P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST001033 | AN001694 | Determination of mode of action of anti-malalrial drugs using untargeted metabolomics | Cultured cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000546 | AN000832 | Multi-omics based identification of specific biochemical changes associated with PfKelch13-mutant artemisinin resistant Plasmodium | Cells | Plasmodium falciparum | Malaria | Monash University | LC-MS |
| ST000539 | AN000818 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) | Cells | Human | Monash University | LC-MS | |
| ST000422 | AN000667 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | LC-MS |
| ST000422 | AN000669 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | LC-MS |
| ST000421 | AN000663 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | LC-MS |
| ST000403 | AN000642 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes | Cells | Human | Monash Institute of Pharmaceutical Sciences | LC-MS | |
| ST000047 | AN000080 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000047 | AN000081 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000046 | AN000076 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | LC-MS |
| ST000046 | AN000077 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (plasma) | Blood | Human | Alzheimers disease | Mayo Clinic | LC-MS |
